Oss-based oncology company Flindr Therapeutics BV has secured €20m  to advance it first-in-class RNF31 inhibitors, which destabilises E3 ubiquitin ligase.

Finnish Nordic Bioproducts Group has opened a production facility to produce advanced cellulosic materials wit the start-up’s AaltoCell technology

From July 10th to 11th, the multidisciplinary Curious2024 – Future Insight™️ Conference is bringing together some of the world’s brightest scientists, including several Nobel laureates, and the most accomplished innovators to present their work and explore the future of science and technology, solving the challenges of today and enabling the dreams of a better tomorrow.

Leiden-based Amarna Therapeutics welcomed Aurelia Caparrós as its new Chief Business Officer (CBO) in April.

The Swiss biotech sector proved robust growth in 2023. Revenues in 2023 increased by CHF500m to CHF7.3bn. Capital investment grew to CHF2bn – just betweeen 2021 (CHF3.4bn) and 2022 (CHF1.3bn).

Ipsen SA and RNA splicing modifier specialist Skyhawk Therapeutics Inc have entered a US$1.8bn licencing option deal in rare neurological disorders.

French drug maker Seabelife SAS will use a €1.5m price money to develop a new dual-acting necroptosis blocker to reduce cell death in geographic atrophy.

Finnish Faron Pharmaceuticals Ltd. announces the appointment of Yrjö Wichmann as Interim Chief Financial Officer. He took over the role in mid-April because his predecessor James O’Brien is leaving Faron to take up another job opportunity outside the company.

Waste based biosurfactants producer Amphistar BV has closed a €6m funding round led by the  European Circular Bioeconomy Fund (ECBF), Qbic III and Flanders Future Tech Fund (FFTF).

Vaccine maker Sumagen Co. Ltd has launched a  cGMP manufacturing partnership with French Naobios SAS for clinical testing of Sumagen’s inactivated HIV vaccine candidate.